Patent details

EP3310809 Title: ANTI-CGRP ANTIBODY FORMULATION

Basic Information

Publication number:
EP3310809
PCT Application Number:
US2016036407
Type:
European Patent Granted for LU
Legal Status:
In force
Application number:
EP167294834
PCT Publication Number:
WO2016205037
First applicant's nationality:
Translation Language:
EPO Publication Language:
English
English Title of Invention:
ANTI-CGRP ANTIBODY FORMULATION
French Title of Invention:
FORMULATION D'ANTICORPS ANTI-CGRP
German Title of Invention:
ANTI-CGRP-ANTIKÖRPERFORMULIERUNG
SPC Number:

Dates

Filing date:
08/06/2016
Grant date:
16/10/2024
EP Publication Date:
25/04/2018
PCT Publication Date:
22/12/2016
Claims Translation Received Date:
Translations Received Date (B1 EP Publication):
Translations Received Date (B2 EP Publication):
Translations Received Date (B3 EP Publication):
Publication date:
16/10/2024
EP B1 Publication Date:
16/10/2024
EP B2 Publication Date:
EP B3 Publication Date:
Lapsed date:
Expiration date:
08/06/2036
Renunciation date:
Revocation date:
Annulment date:

Owner

From:
09/10/2024
 
 

Name:
Eli Lilly and Company
Address:
Lilly Corporate Center, Indianapolis, IN 46285, United States (US)

Agent

Name:
OFFICE FREYLINGER S.A.
From:
18/10/2024
Address:
Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)
To:

Inventor

Name:
SHARMA, Anant N.
Address:
United States (US)

Priority

Priority Number:
201562180905 P
Priority Date:
17/06/2015
Priority Country:
United States (US)

Classification

IPC classification:
C07K 16/18; C07K 16/26; A61K 39/00;

Publication

European Patent Bulletin

1

Issue number:
202442
Publication date:
16/10/2024
Description:
Grant (B1)

2

Issue number:
202444
Publication date:
30/10/2024
Description:
Application number/publication number of the divisional application (Art. 76) changed

Annual Fees

Annual Fee Due Date:
30/06/2025
Annual Fee Number:
10
Annual Fee Amount:
131 Euro
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages
18/10/2024 Power Of Attorney 1
18/10/2024 Outgoing Correspondence 1